KD Logo

Insider Buying: GILEAD SCIENCES, INC., Kyverna Therapeutics Inc. [KYTX] 10% Owner invested 910,000 shares

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Kyverna Therapeutics Inc. shares valued at $20,020,000 were purchased by GILEAD SCIENCES, INC. on Feb 12 ’24. At $22.00 per share, GILEAD SCIENCES, INC. acquired 910,000 shares. The insider’s holdings grew to 4,126,119 shares worth approximately $33.13 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Also, Northpond Ventures III GP, LLC purchased 450,000 shares, netting a total of over 9,900,000 in proceeds. Following the buying of shares at $22.00 each, the insider now holds 450,000 shares.

Before that, Bain Capital Life Sciences Inv had added 450,000 shares to its account. In a trade valued at $9,900,000, the 10% Owner bought Kyverna Therapeutics Inc. shares for $22.00 each. Upon closing the transaction, the insider’s holdings increased to 450,000 shares, worth approximately $25.41 million.

As published in their initiating research note from Wells Fargo on March 04, 2024, Kyverna Therapeutics Inc. [KYTX] has been an Overweight and the price target has been revised to $44. Analysts at Morgan Stanley started covering the stock with ‘”an Overweight”‘ outlook in a report released in early March. As of March 04, 2024, Leerink Partners has initiated its “an Outperform” rating for KYTX. Earlier on March 04, 2024, JP Morgan initiated its rating. Their recommendation was “an Overweight” for KYTX stock.

Analyzing KYTX Stock Performance

During the last five days, there has been a drop of approximately -41.56%. Over the course of the year, Kyverna Therapeutics Inc. shares have dropped approximately -73.23%.

Support And Resistance Levels for Kyverna Therapeutics Inc. (KYTX)

According to the 24-hour chart, there is a support level at 7.50, which, if violated, would cause prices to drop to 6.96. In the upper region, resistance lies at 8.52. The next price resistance is at 9.00. RSI (Relative Strength Index) is 30.38 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -4.17, which suggests the price will decrease in the coming days. Percent R is at 87.06%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Most Popular